Litcius/Paper detail

Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation

N. Chanson, Manuel Ramos‐Casals, Xerxes Pundole, Karijn P.M. Suijkerbuijk, Milton José de Barros e Silva, Merav Lidar, Karolina Benesova, Jan Leipe, Nihan Acar‐Denizli, Pauline Pradère, Jean‐Marie Michot, Anne Laure Voisin, María E. Suarez‐Almazor, Timothy R. D. J. Radstake, Virgínia Fernandes Moça Trevisani, Hendrik Schulze‐Koops, Audrey Melin, Caroline Robert, Xavier Mariette, Robert P. Baughman, Olivier Lambotte, Manuel Ramos‐Casals, Xavier Mariette, Olivier Lambotte, Marie Kostine, Munther A. Khamashta, Leonard H. Calabrese, María E. Suarez‐Almazor, Chiara Baldini, Clifton O. Bingham, Jacques‐Eric Gottenberg, Timothy R. D. J. Radstake, Thierry Schaeverbeke, Hendrik Schulze‐Koops, Pilar Brito‐Zerón, Alejandra Flores-Chávez, Nihan Acar‐Denizli

2021European Journal of Cancer53 citationsDOI

Topics & Concepts

DiscontinuationMedicineImmunotherapySarcoidosisImmune checkpointCTLA-4Immune systemImmunologyDermatologyInternal medicineT cellCancer Immunotherapy and BiomarkersSarcoidosis and Beryllium Toxicity ResearchBrain Metastases and Treatment